Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Centrient CEO Sees New Opportunities From Astral Acquisition

Rex Clements Sets Out Expectations For Integration Of Sterile Injectables Specialist

Executive Summary

Acquiring Astral SteriTech will open up significant new capabilities in sterile injectables for Centrient while also offering an opportunity to expand the reach of the Indian firm’s products through Centrient’s infrastructure, CEO Rex Clements tells Generics Bulletin in an exclusive interview.

You may also be interested in...



Sandoz ‘Bucks Trend’ With Completion Of GSK Cephalosporins Deal

Sandoz has completed the acquisition of GSK’s cephalosporin antibiotics business which includes the Zinnat, Zinacef and Fortum brands in more than 100 markets. Commenting as the deal closed, Sandoz CEO Richard Saynor emphasized the importance of investing in antibiotics. 

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Centrient Acquires India’s Astral SteriTech

Antibiotics specialist Centrient has struck a deal to acquire India’s Astral SteriTech in a move that will expand its portfolio to include sterile injectable finished-dose products.

Related Content

Topics

UsernamePublicRestriction

Register

GB151274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel